Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2015
Reporting Period: Quarter ended September 30, 2015
This filing serves as a notification that the company announced its financial results for the third quarter of 2015. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The filing explicitly states that the full text of the press release with financial details is furnished as Exhibit 99.1. Consequently, the following metrics are not present in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes regarding operations or financial condition are detailed in the provided text. The document only confirms the announcement of results for the period ended September 30, 2015.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, risk factors, or contingencies. It references a press release (Exhibit 99.1) for the full announcement but does not reproduce that content.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2015) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical trial milestones or regulatory updates mentioned in the full press release, as these are not listed in the 8-K cover sheet.
- Confirm the company's cash runway and burn rate from the detailed financial statements referenced in the exhibit.